The Clinical Journal of Oncology says in a new study that researchers with the greatest influence over cancer clinical trials also have the closest financial ties to the pharmaceutical and other industries that benefit from positive clinical trials’ results. This is a disturbing and alarming finding but, unfortunately, not surprising,